News & Updates
Excerpt from the press release: “RADNOR, Pa. and GENEVA, June 24, 2020 (GLOBE NEWSWIRE) — NeuroRx, Inc., in partnership with RELIEF THERAPEUTICS Holding AG (SIX:RLF) “Relief” today announced that the U.S. Food and Drug Administration (FDA) awarded Fast Track Designation to NeuroRx for the investigation of RLF-100 (Aviptadil) for the treatment of acute lung injury/acute…
Read More
Excerpt from the press release: “CARLSBAD, Calif., May 15, 2020 (GLOBE NEWSWIRE) — Leading BioSciences, Inc. (LBS), a drug development company focused on improving human health through therapeutic protection of the intestinal mucosal barrier, today announced the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for a phase…
Read More
Excerpt from the article: “More than a dozen drug firms in Massachusetts are urgently searching for a medicine to treat COVID-19, but the most potent therapy may not end up being a single medication. Instead, medical experts say, the most effective way to battle the disease will likely be a combination of drugs taken together.…
Read More
First detailed analysis of immune response to SARS-CoV-2 bodes well for COVID-19 vaccine development
Excerpt from the article: “Newswise — LA JOLLA, CA—Scientists around the world are racing to develop a vaccine to protect against COVID-19 infection, and epidemiologists are trying to predict how the coronavirus pandemic will unfold until such a vaccine is available. Yet, both efforts are surrounded by unresolved uncertainty whether the immune system can mount…
Read More
Excerpt from the article: “Lessons Learned from a Virtual Town Hall held on May 8, 2020 Much of the daily news focus is on the race to produce vaccines and therapies to combat the spread of COVID-19. While this work is undeniably important, we mustn’t lose sight of what keeps our industry running: the patients…
Read More
Excerpt from the article: “TORONTO, Ontario and CAMBRIDGE, Mass., May 12, 2020 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a company with unique, core technology to predict novel targets on the molecular surface of complex proteins, has advanced its program to develop a high-throughput, highly accurate test for detection of antibodies to…
Read More
Excerpt from the article: “Engineers at the University of California San Diego have developed a remote monitoring platform for patients who have tested positive for COVID-19 but aren’t in need of hospitalization. The system is being tested by patients in a clinical trial at UC San Diego Health. It is intended to help health care…
Read More
Excerpt from the article: “For some COVID-19 patients, the body’s immune response may be as destructive as the virus that causes the disease. The persistent high fevers, severe respiratory distress, and lung damage seen in some critically ill patients are all signs of an immune system in overdrive. Now, a new clinical trial will test…
Read More
Excerpt from the article: “A study published late last week in the New England Journal of Medicine found that hospitalized COVID-19 patients who received Gilead Sciences’ antiviral drug remdesivir recovered a median of 4 days earlier than those who received a placebo. Preliminary findings from the double-blind Adaptive COVID-19 Treatment Trial (ACTT-1), sponsored by the…
Read More
Excerpt from the Article: “The study findings demonstrate x-ray’s value in helping physicians identify, triage, and treat high-risk patients, wrote a team led by Dr. Danielle Toussie of Mount Sinai Hospital in New York City. “We demonstrate how valuable x-rays can be during this pandemic because, by evaluating disease in different portions of the lungs, we…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?